Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia

被引：6

作者：

Kinjyo, Ichiko ^{[1
]}

Matlawska-Wasowska, Ksenia ^{[2
,3
]}

Chen, Xiaoru ^{[4
]}

Monks, Noel R. ^{[5
]}

Burke, Patricia ^{[4
]}

Winter, Stuart S. ^{[2
,3
]}

Wilson, Bridget S. ^{[1
,2
]}

机构：

[1] Univ New Mexico, Dept Pathol, Hlth Sci Ctr, Albuquerque, NM 87131 USA

[2] Univ New Mexico, Ctr Canc, Hlth Sci Ctr, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Div Hematol Oncol, Albuquerque, NM 87131 USA

[4] MedImmune, Translat Med Oncol, Gaithersburg, MD USA

[5] MedImmune, Oncol Res, Gaithersburg, MD USA

来源：

PEDIATRIC BLOOD & CANCER | 2017年 / 64卷 / 11期

关键词：

acute lymphoblastic leukemia; immunotherapy; HEMATOLOGIC MALIGNANCIES; PSEUDOMONAS EXOTOXIN; IMMUNOTOXIN; CAT-8015; TRIAL; HA22; CD22;

D O I：

10.1002/pbc.26604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rg(null) mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models.

引用

页数：4

共 12 条

[1] CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies [J].

Alderson, Ralph F. ;

Kreitman, Robert J. ;

Chen, Tianling ;

Yeung, Peter ;

Herbst, Ronald ;

Fox, Judy A. ;

Pastan, Ira .

CLINICAL CANCER RESEARCH, 2009, 15 (03) :832-839

[2] Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia [J].

Haso, Waleed ;

Lee, Daniel W. ;

Shah, Nirali N. ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance M. ;

Pastan, Ira H. ;

Dimitrov, Dimiter S. ;

Morgan, Richard A. ;

FitzGerald, David J. ;

Barrett, David M. ;

Wayne, Alan S. ;

Mackall, Crystal L. ;

Orentas, Rimas J. .

BLOOD, 2013, 121 (07) :1165-1174

[3] Anti-CD22 therapy in acute lymphoblastic leukaemia [J].

Hoelzer, Dieter .

LANCET ONCOLOGY, 2012, 13 (04) :329-331

[4] Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group [J].

Hunger, Stephen P. ;

Lu, Xiaomin ;

Devidas, Meenakshi ;

Camitta, Bruce M. ;

Gaynon, Paul S. ;

Winick, Naomi J. ;

Reaman, Gregory H. ;

Carroll, William L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1663-1669

[5] Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia [J].

Kreitman, Robert J. ;

Tallman, Martin S. ;

Robak, Tadeusz ;

Coutre, Steven ;

Wilson, Wyndham H. ;

Stetler-Stevenson, Maryalice ;

FitzGerald, David J. ;

Lechleider, Robert ;

Pastan, Ira .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) :1822-1828

[6] Development and Scale-Up of a Commercial Fed Batch Refolding Process for an Anti-CD22 Two Chain Immunotoxin [J].

Linke, Thomas ;

Aspelund, Matthew T. ;

Thompson, Christopher ;

Xi, Guoling ;

Fulton, Andrew ;

Wendeler, Michaela ;

Pabst, Timothy M. ;

Wang, Xiangyang ;

Wang, William K. ;

Ram, Kripa ;

Hunter, Alan K. .

BIOTECHNOLOGY PROGRESS, 2014, 30 (06) :1380-1389

[7] Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia [J].

Mussai, Francis ;

Campana, Dario ;

Bhojwani, Deepa ;

Stetler-Stevenson, Maryalice ;

Steinberg, Seth M. ;

Wayne, Alan S. ;

Pastan, Ira .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (03) :352-358

[8] Characterization of CD22 Expression in Acute Lymphoblastic Leukemia [J].

Shah, Nirali N. ;

Stevenson, Maryalice Stetler ;

Yuan, Constance M. ;

Richards, Kelly ;

Delbrook, Cindy ;

Kreitman, Robert J. ;

Pastan, Ira ;

Wayne, Alan S. .

PEDIATRIC BLOOD & CANCER, 2015, 62 (06) :964-969

[9] Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook [J].

Sullivan-Chang, Loretta ;

O'Donnell, Robert T. ;

Tuscano, Joseph M. .

BIODRUGS, 2013, 27 (04) :293-304

[10] Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial [J].

Wayne, Alan S. ;

Kreitman, Robert J. ;

Findley, Harry W. ;

Lew, Glen ;

Delbrook, Cynthia ;

Steinberg, Seth M. ;

Stetler-Stevenson, Maryalice ;

FitzGerald, David J. ;

Pastan, Ira .

CLINICAL CANCER RESEARCH, 2010, 16 (06) :1894-1903

← 1 2 →